Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × nintedanib × Clear all

Phase

Status

Completed 26 Terminated 5 Unknown 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 49 Radiotherapy 46 Cisplatin 38 Paclitaxel 36 Gemcitabine 35 Cyclophosphamide 34 Carboplatin 32 Dexamethasone 31 Nivolumab 30 Fluorouracil 29 Docetaxel 28 Bevacizumab 28 Oxaliplatin 26 Leucovorin 23 Rituximab 22 Magnetic Resonance Spectroscopy 22 durvalumab 21 Capecitabine 20 Drug Therapy 18 Pemetrexed 17 Cytarabine 17 Radiosurgery 16 Radiation 16 Doxorubicin 16 Bortezomib 16 atezolizumab 15 Prednisone 15 Etoposide 14 fludarabine 13 Lenalidomide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡